Citadel Advisors
MTCR

Citadel Advisors’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Citadel Advisors’s Portfolio MTCR Stock Details MTCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,300
Closed -$8K – 15050
2021
Q4 		$8K Buy
+11,300
New +$20.2K ﹤0.01% 13680

Other funds holding MTCR

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors's MTCR Position: Q4 2022 in Review

Citadel Advisors sold out of Metacrine, Inc. Common Stock (MTCR) in Q4 2022, closing a stake of 136,606 shares — an estimated $66K sold.

Citadel Advisors first reported a position in MTCR in Q3 2020 and held it in 6 quarters. The position peaked at $2.49M in Q3 2020. 29 funds tracked by Wall St. Rank hold MTCR as of Q4 2022.

  • Citadel Advisors reported no remaining Metacrine, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Citadel Advisors sold 136,606 Metacrine, Inc. Common Stock shares in Q4 2022, an estimated $66K.
  • Citadel Advisors first reported a position in Metacrine, Inc. Common Stock in Q3 2020 and held it in 6 quarters.
  • Citadel Advisors's Metacrine, Inc. Common Stock position peaked at $2.49M in Q3 2020.
  • 29 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.